X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

MedChemComm

期刊標題檢索 MEDCHEMCOMM 最新評論: This month we were kicked out of the SCI index. I don't know if we w... (2022-03-05)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[MedChemComm]您好,您是該頁面的第 64104 位訪客。

期刊簡介
期刊名稱MedChemComm MedChemComm

(According to the latest JCR data, this journal is not indexed in the JCR.)
LetPub Score
6.2
50 ratings
Rate

Reputation
7.6

Influence
5.0

Speed
7.0

期刊簡稱MEDCHEMCOMM
ISSN2040-2503
E-ISSN2040-2511
h-index44
CiteScore
CiteScoreSJRSNIPCiteScore Rank
4.700.6660.779
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Drug Discovery
Q248 / 143
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Molecular Medicine
Q283 / 165
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Pharmacology
Q2103 / 301
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Organic Chemistry
Q257 / 183
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Biochemistry
Q2172 / 407
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Pharmaceutical Science
Q243 / 169

自引率 (2023-2024)N.A.自引率趨勢
掲載範囲
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
官方網站http://pubs.rsc.org/en/journals/journalissues/md
在線稿件提交http://mc.manuscriptcentral.com/rsc
開放訪問No
出版商Royal Society of Chemistry
主題領域BIOCHEMISTRY & MOLECULAR BIOLOGY
出版國/地區ENGLAND
發行頻率
創刊年2010
每年文章數0每年文章數趨勢
黃金OA百分比10.61%
Web of Science 四分位
2023-2024
WOS Quartile: Q0

N/A
索引 (SCI or SCIE)
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2040-2503%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Ordinary, 3-8 Week(s)
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【MedChemComm】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    ACS Chemical NeuroscienceH-index: 54

    CiteScore: 9.20
    Nucleic Acid TherapeuticsH-index: 61

    CiteScore: 7.60
    Anti-Cancer Agents in Medicinal ChemistryH-index: 82

    CiteScore: 5.10
    ACS Combinatorial ScienceH-index: 78

    CiteScore: 7.50
    學科內最受檢索的期刊 頁面查看次數
    ACS Chemical Neuroscience90750
    Anti-Cancer Agents in Medicinal Chemistry39430
    ACS Combinatorial Science34048
    Nucleic Acid Therapeutics18758
  •  

    MedChemComm MedChemComm
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [MedChemComm] 的評論撰寫評論
作者: 法慧和同


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-03-05 14:21:54 評論於
This month we were kicked out of the SCI index. I don't know if we will be reinstated in the future
(0) 讚! | 法慧和同

作者: 血天友旋


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-19 23:05:47 評論於
Isn't it June every year?
(0) 讚! | 血天友旋

作者: 坠星倩影


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-18 12:25:35 評論於
Just got kicked out of SCI, be careful everyone
(0) 讚! | 坠星倩影

作者: 维尔娜菲茨杰拉德


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 19:00:15 評論於
The number of corresponding authors for a paper in an SCI journal is not necessarily limited to one, as there is no fixed standard. Different SCI journals have different policies regarding the number of corresponding authors. For SCI journals that only recognize one corresponding author, if a paper lists multiple corresponding authors, the first corresponding author will be automatically selected. For SCI journals that recognize two corresponding authors, two corresponding authors can be listed. The same goes for other requirements. The number of corresponding authors listed by the authors must comply with the regulations of the target SCI journal. The first author of an SCI paper is the person who has made the greatest contribution to the experiment and writing of the paper, and is the person who is listed first in the authors section. In cases of collaborative work, it is common to have multiple co-first authors. There is no specific regulation on the number of co-first authors, as it depends greatly on the workload, length of the paper, publication guidelines, and organizational recognition. Generally, it is common to have 2-4 co-first authors for an SCI paper
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 18:08:04 評論於
Choose a journal from the same publisher that you want to switch to, and submit your manuscript according to the submission requirements of that journal
(0) 讚! | 维尔娜菲茨杰拉德

作者: 修然小公主


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 22:57:23 評論於
How to transfer between different publications of the same magazine?
(0) 讚! | 修然小公主

作者: 八坂篷蔚


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 15:34:53 評論於
How many corresponding authors can there be at most? How many first authors can there be at most?
(0) 讚! | 八坂篷蔚

作者: 潜龙雨真


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-10-23 19:48:26 評論於
Can you tell me the format for citing references?
(0) 讚! | 潜龙雨真

作者: 凌霄高洁


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-18 19:18:35 評論於
Everything can only hope for next year, after all, if the overall is rising, there is no need to worry. Even if it only rises a little bit in a year, it is still good in accumulation
(0) 讚! | 凌霄高洁

作者: 星熊惜筠


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-06-17 23:41:00 評論於
Review Speed: 1.0 | Submission Acceptance Rate: 50.0 Experience Sharing: The review speed is really fast, the editor is very responsible. I submitted on April 12th, and the review came back in about 15 days with major revisions. However, the problems were not significant. It took me two weeks to collect data and finally the article was accepted for publication. The whole process took less than two months. Grateful, I will continue to consider this journal in the future
(0) 讚! | 星熊惜筠

作者: 匿名


領域: 生命科学
審稿時間: 0.0 month(s)
結果:


撰寫評論

2013-07-12 21:52:00 評論於
 (0) 讚! | 匿名  

作者: 凌霄高洁


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2013-02-10 18:52:37 評論於
Plant chemistry demands new compounds that exhibit strong activity. However, the review process is slow and not easily accepted
(0) 讚! | 凌霄高洁

作者: Horace Mike


領域:
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2013-01-24 23:20:10 評論於
The new magazine from RSC has a difficulty level similar to that of BMCL, with a faster first review process taking around one and a half months
(0) 讚! | Horace Mike

作者: 匿名


領域: 医药科学
審稿時間: 0.0 month(s)
結果:


撰寫評論

2013-01-24 22:29:00 評論於
RSC's new journal. The difficulty is similar to BMCL. Initial review is fast, one and a half months.

(0) 讚! | 匿名

作者: 匿名


領域: 生命科学
審稿時間: 0.0 month(s)
結果:


撰寫評論

2012-12-03 22:25:00 評論於
 (0) 讚! | 匿名  

作者: 匿名


領域:
審稿時間: 0.0 month(s)
結果:


撰寫評論

2012-02-23 13:24:00 評論於
Journal Homepage URL: http://pubs.rsc.org/en/journals/journalissues/md
(0) 讚! | 匿名

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [MedChemComm] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*